<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315779</url>
  </required_header>
  <id_info>
    <org_study_id>20-2.1T/40</org_study_id>
    <nct_id>NCT04315779</nct_id>
  </id_info>
  <brief_title>Comparison of Two Different Approaches in the Surgical Treatment of Tubal Ectopic Pregnancy</brief_title>
  <official_title>Comparison of Conventional Laparoscopy and Natural Orifice Transluminal Endoscopic Surgery in the Surgical Treatment of Tubal Ectopic Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we aim to compare conventional laparoscopy and natural orifice transluminal
      endoscopic surgery in the surgical treatment of ectopic pregnancy.

      All the patients, with an indication of surgery for ectopic pregnancy, will be asked to
      participate in this clinical trial.

      Indication of surgery will be based on clinical findings, ultrasound scans and serum hcg
      levels. There will be no exclusion criteria.

      Duration of surgery, successful completion of the operation, intraoperative data and
      postoperative data will be collected.

      All the patients will be asked to fill out quality of recovery-40 (QoR-40) questionnaire and
      36-item short form health survey (SF-36) before surgery.

      QoR-40 questionnaire will be repeated 24 hours after surgery and repeated every 24 hours
      until discharge. SF-36 will be repeated at 1-month follow-up visit. Patients will be also
      evaluated at postoperative 3-months, and female sexual function index will be asked to be
      filled-out.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">May 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful completion of surgery as intended</measure>
    <time_frame>Intraoperative, from the beginning to the end of surgical intervention</time_frame>
    <description>The completion of the surgery with the route planned without having to change the surgical route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Operating time</measure>
    <time_frame>Intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>During follow-up, after surgery until hcg level drops below 5 U/L, up to 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>During follow-up, after surgery until hcg level drops below 5 U/L, up to 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery-40 questionnaire</measure>
    <time_frame>Preoperatively and Postoperative every 24 hours until discharge, expected to be up to 3 days following surgery</time_frame>
    <description>The Quality of Recovery 40 questionnaire will be self-administered by patients at different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life change</measure>
    <time_frame>Preoperative, Postoperative 1-month</time_frame>
    <description>Short form 36 item health survery (SF-36) questionnaire will be self-administered by patients at different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>Postoperative 2 hours, 6 hours, 12 hours, 24 hours, and every 24 hours until discharge (if the patient stays longer than 1 day at the hospital), , expected to be up to 3 days following surgery</time_frame>
    <description>Postoperative pain will be assessed on a 10-cm visual analog scale at different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>Postoperative 3 months</time_frame>
    <description>Female sexual function index (FSFI) questionnaire will be self-administered by patients at postoperative 3-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for additional analgesic use</measure>
    <time_frame>Postoperative period until discharge, expected to be up to 3 days following surgery</time_frame>
    <description>Patients will be routinely administered pethidine hydrochloride 3x50 mg parenteral on the day of surgery. Starting from postoperative day 1 patients will be administered paracetamol 500 mg oral upon their request. In case of inadequate pain relief and the need for additional analgesic use will ve recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ectopic Pregnancy</condition>
  <arm_group>
    <arm_group_label>Conventional laparoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, patients will be treated via conventional laparoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transvaginal natural orifice transluminal endoscopic surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salpingectomy</intervention_name>
    <description>Patients will undergo removal of the affected tube</description>
    <arm_group_label>Conventional laparoscopy</arm_group_label>
    <arm_group_label>Transvaginal natural orifice transluminal endoscopic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18 years of age,

          -  Diagnosis of tubal ectopic pregnancy

          -  Patient's preference to undergo salpingectomy

        Exclusion Criteria:

          -  Patients with contraindication to endoscopic surgery

          -  Refusal to sign informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gokay Ozceltik</last_name>
    <phone>+905330922020</phone>
    <email>gokayozceltik@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ege University University Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gokay Ozceltik</last_name>
      <phone>+905330922020</phone>
      <email>gokayozceltik@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Gokay Ozceltik</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>natural orifice transluminal endoscopic surgery</keyword>
  <keyword>laparoscopy</keyword>
  <keyword>ectopic pregnancy</keyword>
  <keyword>minimally invasive surgery</keyword>
  <keyword>quality of life</keyword>
  <keyword>sexual function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy, Ectopic</mesh_term>
    <mesh_term>Pregnancy, Tubal</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

